Secura Bio, Inc. ( an integrated pharmaceutical company maximizing commercial outcomes for oncology medicines, today announced a poster presentation highlighting extended follow up analyses examining ...

Oslo, 4 November 2025: Reference is made to the stock exchange notice published by Zelluna ASA (the "Company") on 3 November 2025 regarding the successful private placement and retail offering.

Propanc Biopharma, Inc. (Nasdaq: PPCB) is developing a novel approach to prevent recurrence and metastasis in cancer patients by targeting and eradicating cancer stem cells through the activation of ...

The UAB site joins the list of clinical centers participating in the Company’s global Phase 1/1b trial, which is designed to assess the safety, tolerability, pharmacokinetics (PK), and ...

Initial results of a Phase 1 / 2 open label study of AT-02, the company’s lead pan-amyloid removal therapeutic candidate, in patients with AL amyloidosis will be presented at ASH. The presentation ...

AMT-143 is a long-acting local analgesic for postsurgical pain control. It is administered via instillation at the time of the surgery. In a Phase 1 study, AMT-143 demonstrated sustained release of ...

MINNEAPOLIS, Nov. 04, 2025 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced its ...

Purespring co-author paper with real world evidence on epidemiological prevalence data of NPHS2 pathogenic variants across global populations London – 4 November 2025 – Purespring Therapeutics, a ...

Neuronetics Reports Third Quarter 2025 Financial and Operating Results and Announces CEO Transition Plan Delivered $37.3 million total revenue in Q3 2025, representing 11% adjusted pro forma revenue ...

Incyte secures an exclusive option to acquire Prelude’s mutant selective JAK2V617F JH2 inhibitor program. Mutant selective JAK2V617F JH2 inhibitors have disease-modifying potent ...

Cash balance of $344.8 million as of September 30, 2025, together with net proceeds of ~$445 million from October 2025 equity offering, with expected runway into 2028 BEDFORD, Mass., Nov. 04, 2025 ...

Lausanne, Switzerland, November 4, 2025 -- AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company pioneering precision therapeutics for neurodegenerative diseases, today reported ...